Novartis/$NVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis Metrics
BasicAdvanced
$241B
17.13
$7.30
0.57
$2.60
2.08%
Price and volume
Market cap
$241B
Beta
0.57
52-week high
$133.55
52-week low
$96.06
Average daily volume
1.8M
Dividend rate
$2.60
Financial strength
Current ratio
0.881
Quick ratio
0.583
Long term debt to equity
54.161
Total debt to equity
71.554
Dividend payout ratio (TTM)
54.32%
Interest coverage (TTM)
18.35%
Profitability
EBITDA (TTM)
24,923
Gross margin (TTM)
76.25%
Net profit margin (TTM)
25.53%
Operating margin (TTM)
36.29%
Effective tax rate (TTM)
12.40%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
12.13%
Return on equity (TTM)
32.62%
Valuation
Price to earnings (TTM)
17.127
Price to revenue (TTM)
4.339
Price to book
4.39
Price to tangible book (TTM)
-18.98
Price to free cash flow (TTM)
14.265
Free cash flow yield (TTM)
7.01%
Free cash flow per share (TTM)
8.763
Dividend yield (TTM)
2.08%
Forward dividend yield
2.08%
Growth
Revenue change (TTM)
12.88%
Earnings per share change (TTM)
-14.91%
3-year revenue growth (CAGR)
7.00%
10-year revenue growth (CAGR)
1.08%
3-year earnings per share growth (CAGR)
-9.39%
10-year earnings per share growth (CAGR)
-0.19%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Bulls say / Bears say
The company’s third-quarter operating income rose 6% year-over-year to $5.46 billion, driven by strong sales of new oncology and rare disease therapies, demonstrating resilience amid its core franchise’s patent challenges. (Reuters)
A positive Phase III PSMAddition trial readout for Pluvicto in earlier-stage prostate cancer paves the way for broader label expansion and potential significant market growth in radioligand therapy. (Reuters)
The initiation of a up-to-$10 billion share buyback program through 2027 underscores robust free cash flow generation and management’s confidence in the company’s financial outlook. (Reuters)
Analysts forecast Entresto sales to fall from over $8 billion in 2025 to about $6 billion in 2026 following generic competition, threatening a key revenue pillar. (Reuters)
Cosentyx revenue plateaued at $1.7 billion amid intensifying competition in the psoriasis market, highlighting pressure on established brands. (Reuters)
The substantial M&A and licensing outlay—up to $30 billion including a $12 billion Avidity acquisition—raises concerns over integration risks and elevated capital deployment potentially denting margins. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $241B as of November 05, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 17.13 as of November 05, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of November 05, 2025, the dividend rate is $2.59609 and the yield is 2.08%. Novartis has a payout ratio of 54.32% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.